Stifel analyst Thomas Shrader reiterated a Buy rating and $430 price target on Biogen (NASDAQ: BIIB) saying SPINRAZA confusion is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE